 Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2009 | 10 | 2 | 12 | | 2010 | 4 | 0 | 4 | | 2011 | 11 | 1 | 12 | | 2012 | 15 | 1 | 16 | | 2013 | 15 | 0 | 15 | | 2014 | 19 | 2 | 21 | | 2015 | 24 | 3 | 27 | | 2016 | 19 | 3 | 22 | | 2017 | 28 | 1 | 29 | | 2018 | 23 | 2 | 25 | | 2019 | 23 | 1 | 24 | | 2020 | 15 | 1 | 16 | | 2021 | 22 | 0 | 22 | | 2022 | 36 | 0 | 36 | | 2023 | 31 | 0 | 31 | | 2024 | 22 | 4 | 26 | | 2025 | 16 | 3 | 19 | | 2026 | 9 | 2 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Cooley JC, Penick SK, Wilson JA, Javkhlan N, Foster DG, Edelman BL, Schott CA, Humphries SM, Lynch DA, Schwartz DA, Riches DWH, Redente EF. Nintedanib increases BCL-2 in fibrotic fibroblasts, enhancing ABT-199 apoptosis and fibrosis resolution. Am J Respir Cell Mol Biol. 2026 Aug 01; 74(8):1103-1113.
-
Chumpagern W, Spagnolo P, Ratanawatkul P, Mohning MP, Fernández Pérez ER. Prognostic value of ventilatory efficiency in hypersensitivity pneumonitis. BMJ Open Respir Res. 2026 Jul 09; 13(1).
-
Peljto AL, Furusawa H, Puthenvedu D, Lee JS, Steele MP, Brancato J, Cardwell J, Blumhagen RZ, de Andrade J, Bendstrup E, Blackwell TS, Bonella F, Borie R, Braybrooke R, Brown KK, Carbone RG, Christie JD, Costabel U, Crestani B, Davidsen JR, Dieude P, Donnelly SC, Egan J, Eickelberg O, Fernández Pérez ER, Fiddler CA, Foster EE, Gibson KF, Gudmundsson G, Guthridge JM, Henry MT, Hirani N, Jenkins RG, Kass DJ, Keane MP, Kokturk N, Kropski JA, Lederer D, Leone PM, Linderholm AL, Maher TM, Mathai SK, McCarthy C, McElroy AN, Mogulkoc N, Molina-Molina M, Molyneaux PL, Montesi SB, Nathan SD, Noth I, Olaniyi JA, Oldham JM, O'Reilly KMA, Palmisciano AJ, Pardo A, Parfrey H, Planas-Cerezales L, Poletti V, Porteous MK, Puppo F, Richeldi L, Rojas M, Salinas M, Schluger N, Selman M, Shea BS, Sterclova M, Solomon JJ, Tomassetti S, Vasakova MK, Zhang Y, Corte TJ, Dickinson JL, Glaspole I, Moodley YP, Prele CMA, Ryerson CJ, Wolters PJ, Jinno M, Miyata Y, Akagawa S, Narumoto O, Kita T, Shibayama T, Li T, Owan I, Wakamatsu K, Arai T, Hirose M, Kim DS, Ohta K, Ohta S, Park JS, Park MS, Yang IV, Fingerlin TE, Miyazaki Y, Okamoto T, Inoue Y, Song JW, Schwartz DA. Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations. Am J Respir Crit Care Med. 2026 07 01; 212(7):1522-1532.
-
Sakamachi Y, Wiley E, Trempus CS, Jacobs H, Solis A, Johnson CG, Meng X, Hussain S, Roselli A, Lipinski JH, O'Dwyer DN, Randall TA, Malphurs J, Papas B, Wu BG, Li Y, Kugler MC, Mehta S, Scappini E, Thomas SY, Li JL, Zhou L, Karmaus PW, Lih FB, Fessler MB, McGrath JA, Gibson K, Kass DJ, Gleiberman A, Andrianova E, Walts A, Invernizzi R, Molyneaux PL, Yang IV, Zhang Y, Kaminski N, Segal LN, Schwartz DA, Gudkov AV, Garantziotis S. Toll-like receptor 5 protects against murine lung fibrosis through reduced dysbiosis, and TLR5 deficiency is associated with human IPF. Sci Transl Med. 2026 Jun 03; 18(852):eadw1028.
-
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Brown KK, Koucký V, Weinman JP, Simmons J, Dumistracel M, Jantzen F, Gahlemann M, Griese M. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. Pediatr Pulmonol. 2026 Jun; 61(6):e71707.
-
Wang Y, Hennessy C, Dobrinskikh E, Humphries SM, Hatakka K, Ackert-Bicknell CL, Godfrey DA, Kelada SNP, Keele GR, Cardwell J, Peljto A, Clouthier DE, Yang IV, Schwartz DA. Genes, other than Muc5b, are associated with bleomycin-induced lung injury. Commun Biol. 2026 May 12; 9(1).
-
Zöller M, Mastalerz M, Dick E, Merl-Pham J, Hennen E, Prakki SRS, Chakraborty A, Nakayama M, Klotz M, Marchi H, LeGleut R, De Sadeleer LJ, Wuyts WA, Vanaudenaerde BM, Jeridi A, Prasse A, Jäger B, Santofimia-Castaño P, Stoleriu MG, Hilgendorff A, Hauck SM, Yildirim AÖ, Schiller H, Staab-Weijnitz CA. Nuclear protein 1 is a cell death regulator in primary human airway epithelial cells and reduced in idiopathic pulmonary fibrosis. Sci Rep. 2026 May 11; 16(1).
-
Blumhagen RZ, Kurche JS, Cool CD, Heinz D, Ma X, Davidson EJ, Fingerlin TE, Huber JP, Dobrinskikh E, Schwartz DA, Yang IV. Ectopic expression of MUC5B in the respiratory bronchiole initiates endoplasmic reticulum stress in the IPF lung. Am J Respir Cell Mol Biol. 2026 05 01; 74(5):632-643.
-
Konkol SB, Huang Y, Ma SF, Humphries SM, Lynch DA, Paul T, Malik N, Strickland E, Mannem H, Oldham JM, Adegunsoye A, Newton CA, Oh A, Martinez F, Sperling AI, Kim JS, Noth I. The Role of Matrix Metalloproteinase 12 in Distinguishing Idiopathic Pulmonary Fibrosis From Fibrotic Hypersensitivity Pneumonitis. Chest. 2026 Jul; 170(1):157-168.
-
Redente EF, Song T, Javkhlan N, Edelman BL, Foster DG, Wilson JA, Chakraborty S, Cooley JC, Gaurav R, Saguthi S, Seibold MA, Blumhagen RZ, Schwartz DA, Yang IV, Matsuda J, Bridges JP, Zemans RL, Tuder RM, Riches DWH. Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition. Nat Commun. 2026 Feb 28; 17(1).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|